f32-microglobulin (J2m), whose association with the heavy chain is required for functional surface membrane expression of the complete product. These molecules control the recognition of antigen by cytotoxic T lymphocytes, different allele products varying in their ability to present alternative antigen epitopes (1, 2) . The antigen specificity of target-cell killing by cytotoxic T lymphocytes is thought to be mediated by the binding of the T-cell antigen receptor to processed antigen complexed with target-cell HLA-A,B,C molecules. T-lymphocyte killing of target cells also requires lymphocyte CD2 antigen to bind target-cell lymphocyte function-associated antigen 3 (LFA-3) (3, 4) . This receptor-ligand interaction increases the adhesion between cells in a non-antigen-specific manner.
The observation that some tumor-derived cell lines lack surface expression of HLA-A,B,C molecules (5-7) led to the suggestion that tumors expressing tumor-specific antigens could escape from T-cell immune attack through the selective outgrowth of HLA-A,B,C loss variants. This idea has subsequently been supported by many examples of loss of HLA-A,B,C expression from tumors, by using immunohistochemical techniques (for review, see ref. 8 ). Approximately 1%o of colorectal adenocarcinomas completely lack expression of HLA-A,B,C antigens (refs. 8 and 9 and P. Richman and W.F.B., unpublished data), which are consistently strongly expressed in normal colorectal epithelium. The loss of some HLA-A,B,C allele products with the retention of others within single colorectal adenocarcinomas has been described (10) (11) (12) , and this selective loss of allele products is also most probably important in escape from tumor immunity. This is also likely to be the case for a loss of tumor-cell This study investigates the expression of HLA-A,B,C allele products and LFA-3 in a series of 10 colorectal adenomas and 30 adenocarcinomas, extending the results of a preliminary communication (10) .
MATERIALS AND METHODS
Tissues. Samples from 10 colonic adenomas (cases 1-10, Table 1 ) and 30 colonic adenocarcinomas (cases 11-40) from a total of 40 patients were kindly supplied by the Imperial Cancer Research Fund Colorectal Unit and Pathology Department, Saint Mark's Hospital, London. Nine of the adenomas (cases 1-9) arose in patients suffering from familial adenomatous polyposis. All 9 measured 1 cm or less in maximum diameter and were of tubular histology. One adenoma (case 10) was solitary, of tubulo-villous histology and measured 6.5 cm in maximum diameter. One adenocarcinoma (case 12) arose in a patient with ulcerative colitis. Non-neoplastic colonic epithelium was present in the same tissue block as 4 adenocarcinomas and histologically normal colonic mucosa was also separately sampled in 7 adenomas and 15 adenocarcinomas. In adenocarcinoma patients, the sample of normal colon was taken approximately 10 cm from the edge of the tumor. Tissues were snap frozen in liquid nitrogen-cooled isopentane and subsequently stored under liquid nitrogen.
Monoclonal Antibodies (mAbs) and HLA Determinants. The mAbs, used as primary reagents in the form of tissue culture supernatants, and their specificities are as follows: BBM.1 detects f32m (13) ; HC-10 detects HLA-A,B,C free heavy chain with a preference for HLA-B products (14) ; PA2.6 and W6/32 detect all f82m-associated HLA-A,B,C antigens (6, 15) tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. A,B,C allele products was demonstrated by their reactivity on tumor stroma in a series of 12 breast carcinomas that had been HLA-typed (J.G.B., unpublished data) by standard techniques (20) (vol/vol) normal human serum and then by peroxidaseanti-peroxidase complexes (Dakopatts; 1:100 dilution for 45 min) in PBS. All antibody incubations were followed by two 5-min washes in PBS. The peroxidase was developed in 3,3'-diaminobenzidine (Sigma) at 1 mg/ml in PBS containing 0.3% hydrogen peroxide. Sections were washed in tap water for 10 minm counterstained with hematoxylin, cleared, and mounted in D.P.X. mounting medium (BDH) .
Assessment. Presence of immunohistochemical staining in epithelium and stroma was assessed in normal and neoplastic colonic tissue. A limited patient HLA-A,B,C type was deduced from the reaction of mAbs directed against polymorphic HLA-A,B,C determinants with tumor stroma and, where available, normal colorectal mucosa.
An HLA-B17 phenotype was deduced from stromal staining with mAb MA2.1 and lack of staining with mAb BB7.2. The proportion of tumor cells stained by each mAb was assessed semi-quantitatively (see Table 1 Though none of the 10 adenomas studied contained areas that had lost all HLA-A,B,C antigens from tumor cells, two showed focal loss of an HLA-B product. One adenoma (case 2) contained a glandular focus comprising some 1o of the section in which, in contrast to surrounding glands, HLABw4 was undetectable. HLA-Bw4-positive and -negative areas were morphologically indistinguishable. A second adenoma (case 10), the solitary (nonpolyposis), large tubulovillous adenoma, showed an area of HLA-B17 loss comprising 50% of the tumor (Fig. 1) (9) bearing tumor-specific antigens but not expressing HLA-A,B,C antigens to escape destruction by cytotoxic T lymphocytes.
The underlying defect in the single case failing to express any HLA-A,B,C antigen was a failure to produce f32m, which is essential for the surface expression of these molecules (5, 23). The same defect has been identified in the Burkitt lymphoma cell line Daudi (5, 24) and the colorectal adenocarcinoma cell line LoVo (7). The loss or down regulation of some HLA-A,B,C allele products, with the retention ofothers, has been demonstrated in Burkitt lymphoma (25) and colorectal adenocarcinoma (10) (11) (12) and similar losses of the equivalent molecules in murine tumors have been documented (26) . Extending our earlier observations, we have found such selective allele product loss to be very common in colorectal adenocarcinomas, complete tumor HLA-A2 loss occurring in 7 of 13 HLA-A2-positive patients. These selective losses may have important functional consequences because of variation in the ability of various allele products to present different antigen epitopes to cytotoxic T lymphocytes (1, 2) . Thus, in some cases, the loss of single allele products may be functionally equivalent, in terms of escape from T-cell attack, to the loss of all HLA-A,B,C molecules. Complete tumor HLA-A2 loss (in 7 of 13 cases) occurred significantly more frequently than complete losses of HLA-A1 (0 of 6 cases) and HLA-A3 (1 of6 cases) (P < 0.05). This suggests that HLA-A2 antigen may be the most effective of the three allele products studied here in presenting a common tumor antigen to cytotoxic T-cell attack. None of the 10 adenomas examined contained areas lacking all HLA-A,B,C antigens, but 2 showed well demarcated foci, demonstrating selective loss of HLA-B products. Such areas of allele product loss can, therefore, arise relatively early in tumor development and may, of course, represent the precursors of the more extensive areas of allele product loss seen in the adenocarcinomas.
Selective HLA-A,B,C allele product loss in colorectal adenocarcinoma may occur with such high frequency because it can result from a single genetic mutation. In contrast, loss of all HLA-A,B,C products usually requires two mutations. However, loss of HLA-A,B,C allele products could simply be a marker of chromosomal loss, the gene whose loss is selected for lying elsewhere on chromosome 6. The combined loss of HLA-A2 and Bw4 specificities in several cases is consistent with the deletion of at least a considerable portion of one HLA region. The apparently nonrandom loss of tumor HLA-A products (HLA-A2 loss occurred significantly more than Al and A3 loss) and, in case 14, the loss of tumor A2 antigen with the retention of the Bw4 and Bw6 antigens, which would be consistent with a small genetic defect involving only the HLA-A gene, argue that it is the loss of HLA allele products themselves that is selected for.
LFA-3 was strongly expressed on all cases of normal colorectal mucosal epithelium examined but was completely absent from tumor cells in 1 of 20 adenocarcinomas. Because LFA-3 is thought to increase the strength of adhesion between cytotoxic T lymphocytes and their targets, its loss, like that of HLA-A,B,C antigens, could allow tumor cells to escape T-cell killing. Loss of LFA-3 has also been described in some cases of Burkitt lymphoma (27) , a tumor expressing foreign Epstein-Barr virus antigens. Though ICAM-1 was not detected on normal colorectal mucosal epithelium, it was expressed focally in 2 of 20 adenocarcinomas examined. The appearance of tumor ICAM-1 may reflect its ease of inducibility by a number of agents, such as interferon y (28) .
The loss of LFA-3 and of individual HLA-A,B,C allele products from tumor cells may be selected for through an advantage in escape from T-cell killing. However, tumorspecific antigens have not been well characterized. The demonstration that cytotoxic T lymphocytes can recognize short peptides that arise from the intracellular processing of antigen (29, 30) extends the range of candidate tumor-specific antigens to the intracellular products of mutated oncogenes. For example, products of the RAS gene family, which have an intracellular localization, could act as tumor antigens, detectable by host cytotoxic T lymphocytes, in the approximately 50%o of colorectal adenocarcinomas possessing a mutated RAS gene (31) . Because HLA-A,B,C antigen loss presumably results from immune selection directed against neoplastic cells bearing tumor-specific antigens, HLA-A,B,C-lacking tumor cell lines will probably be the best cell types in which to characterize such tumor antigens. The clinical detection of tumor antigens at an early stage in tumor progression, before the outgrowth of mutants that can evade an immune response, may become an important indication for patient immunotherapy.
